Table 2.
Summaries of outcomes over the course of the study
| Treatment |
Dose |
N |
SBP (mm Hg) |
Serum K+ (mmol/l) |
Weight (kg) |
|||
|---|---|---|---|---|---|---|---|---|
| All patients | Mean | SD (SE for Δ) | Mean | SD (SE for Δ) | Mean | SD (SE for Δ) | ||
| Amiloride | Baseline | 9 | 123 | 16 | 4.4 | 0.4 | 82.5 | 20.5 |
| ΔLow | 8 | -5.1 | 4.5 | 0.9 | 0.2 | -0.9 | 0.6 | |
| ΔHigh | 7 | -0.1 | 4.6 | 0.6 | 0.2 | -0.1 | 0.7 | |
| HCTZ | Baseline | 9 | 127 | 13 | 4.4 | 0.3 | 83.0 | 21.8 |
| ΔLow | 9 | -8.0 | 4.4 | 0.0 | 0.2 | -0.6 | 0.6 | |
| ΔHigh | 9 | -10.2 | 4.4 | -0.1 | 0.2 | -0.3 | 0.6 | |
| High plasminogen | Mean | SD / error (for Δ) | Mean | SD / error (for Δ) | Mean | SD / error (for Δ) | ||
|---|---|---|---|---|---|---|---|---|
| Amiloride | Baseline | 4 | 135 | 14 | 4.5 | 0.3 | 91.3 | 24.9 |
| ΔLow | 4 | -11.8 | 6.7 | 1.0 | 0.3 | -0.7 | 0.8 | |
| ΔHigh | 3 | -0.9 | 7.1 | 0.9 | 0.3 | 0.3 | 0.9 | |
| HCTZ | Base | 4 | 131 | 19 | 4.5 | 0.3 | 93.8 | 25.4 |
| ΔLow | 4 | -10.1 | 6.7 | 0.1 | 0.3 | -1.1 | 0.9 | |
| ΔHigh | 4 | -9.0 | 6.7 | -0.1 | 0.3 | -0.9 | 0.9 | |
| Low plasminogen | Mean | SD / error (for Δ) | Mean | SD / error (for Δ) | Mean | SD / error (for Δ) | ||
|---|---|---|---|---|---|---|---|---|
| Amiloride | Baseline | 5 | 113 | 10 | 4.2 | 0.4 | 75.5 | 15.3 |
| ΔLow | 4 | 1.4 | 6.4 | 0.8 | 0.3 | -1.0 | 0.8 | |
| ΔHigh | 4 | 1.1 | 6.3 | 0.4 | 0.3 | -0.5 | 0.8 | |
| HCTZ | Base | 5 | 123 | 5 | 4.3 | 0.2 | 74.4 | 16.0 |
| ΔLow | 5 | -6.7 | 6.0 | 0.0 | 0.3 | -0.2 | 0.8 | |
| ΔHigh | 5 | -11.8 | 6.0 | -0.2 | 0.3 | 0.1 | 0.8 | |
Baseline estimates are simple averages and SDs obtained across study participants at the appropriate period. ΔLow and ΔHigh estimates are estimates of change from baseline for the study participants at the end of the low-dose and high-dose periods, respectively. Summaries are presented overall and stratified by urinary plasminogen plus plasmin per gram of creatinine.